跳至主要内容
临床试验/jRCT2080222240
jRCT2080222240已完成2 期

Open-label study to assess efficacy and safety of a single dose (i.v.) of NMK36 in subjects with high / low- grade glioma.

Nihon Medi-Physics Co., Ltd.1 个研究点目标入组 35 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
35
试验地点
1
主要终点
safety

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Non-randomized, Open-label, Uncontrolled
主要目的
Diagnostic Purpose

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Patients who were clinicaly-suspected with high / low- grade glioma by the clinical sign / course and MRI exam are to have the surgical removal of the tumor.

排除标准

  • Patients who received treatment for glioma.
  • Patients who received chemotherapy for malignant tumor within the last 5 years.
  • Patients who are pregnant, lactating or possibly pregnant.
  • Patients who have hepatic or renal dysfunction.
  • Patients with Karnofsky performance status below 40%.

结局指标

主要结局

safety

subjective/objective symptoms, electrocardiogram exam, vital signs, clinical tests

efficacy

positive-predictive value of PET imaging in the regions which are not visualized by contrast T1-weighted MRI

次要结局

未报告次要终点

研究者

研究点 (1)

Loading locations...

相似试验